Breast Cancer

Depression can affect the trajectory of treatment and associated outcomes.

Capivasertib combined with fulvestrant doubled progression-free survival in patients with recurrent or progressed advanced stage HR-positive HER2-negative breast cancer compared to placebo.

There are 8 million cancer survivors who may have limitations in their daily functional ability.

The meeting aims to bring together pharmacists to discuss solutions for responding to the rapidly evolving evidence and needs for effective implementation.

When physicians followed up, rates of screening improved for breast and cervical cancer by 50% and 250%, respectively, among eligible cancer survivors.

FR alpha expression is limited on normal cells, but upregulated on cancers such as ovarian, endometrial, and triple-negative breast cancers.

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.

Program Chair Ryan Haumschild, PharmD, MS, MBA, discussed what attendees can look forward to at the inaugural Oncology Pharmacists Connect meeting.

Specialty pharmacists—those caring for patients with serious, sometimes life-threatening conditions such as cancer or rheumatologic disease—are not immune from the ongoing labor crisis.

The imaging agent and visualization system will be an adjunct to standard of care to reduce residual cancer in the lumpectomy cavity during initial surgery.

US Preventive Services Task Force also called for more research into how to address screening and treatment disparities faced by racial and ethnic minorities.

Alpelisib plus the antioxidant N-acetylcysteine sensitizes NF1 knockout cells to PI3Kα inhibition and reverts their glycolytic phenotype in patients with advanced forms of breast cancer.

Study examines association between breast cancer survival and neighborhood-level measures such as socioeconomic status.

The system is considered effective at identifying residual breast cancer following surgical resection.

Infusion reactions in the switching group did not occur with switching, but rather only with reference trastuzumab administration.

Study results show significant differences in pCR rates, but the differences were not subtype-specific.

Oncology pharmacist discusses recent clinical trial data and what it could mean for patient outcomes.

Certain populations have been found to have differing prognoses, such as African American patients, who have an earlier onset of disease with a higher likelihood of an aggressive tumor type and shorter survival.

The implementation of genetic testing for patients prescribed medications associated with progressive multifocal leukoencephalopathy is likely to improve safety outcomes.

Ribociclib plus endocrine therapy demonstrates a reduction in the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

Drugs such as pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan all have growing bodies of evidence illustrating which patients with cancer are most likely to benefit and in which settings.

3D biofabrication models reflect increasing global awareness of the ethics of preclinical studies and an increased need for determining therapeutic efficacy differences.

Therapy effectively treats cells harboring HR deficiencies, including those of specific types of ovarian, breast cancers.

Most patients used nonproprietary drugs, which may contribute to the reduction of out-of-pocket costs for the treatment of invasive breast cancer.

The vaccine targets a protein that is no longer found after lactation in normal aging tissues but is present in most triple-negative breast cancers.

The approach was based on previous research suggesting that foods rich in carotenoids, lycopene, certain B vitamins, and omega 3 fatty acids improved fatigue in survivors of breast cancer.

Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.

Incidence of regional tumor recurrence in patients with HR–positive breast cancer did not significantly differ between patients who received post operational radiotherapy.

Numerous clinical trials are investigating the next generation of PARPi.

Cancer screening rates were still below the expected rates of return in both 2021 and 2022.